[Expressions of HLA class I antigen and CD8 and their clinical significance in cervical cancer].
OBJECTIVE
To examine the expressions of HLA class I antigen and CD8 in various cervical diseases and investigate their association with cervical cancer.


METHODS
The expressions of HLA class I antigen and CD8 in cervical tissues sampled from patients with cervical cancer, cervical intraepithelial neoplasia (CIN), and chronic cervicitis were detected using SP immunohistochemistry. The association of the expressions of HLA class I antigen and CD8 with the clinicopathologic indices of the patients was analyzed.


RESULTS
The positive expression rates of HLA class I antigen in cervical cancer, CIN, and chronic cervicitis were 22.6%, 100.0%, and 100.0%, and the positive expression rates of CD8 were 22.6%, 95.5%, and 100.0%, respectively. The positive rates of HLA class I antigen and CD8 were significantly lower in patients with cervical cancer (P<0.01). Patients with stage I cervical cancer had significantly higher positive rates of HLA class I antigen and CD8 than those with stage II cervical cancer (46.7% vs 0.0%, 46.7% vs 0.0%, both P<0.01). The expressions of HLA class I antigen and CD8 decreased with the progression of the clinicopathological stages, and may even become undetectable. The expressions of HLA class I antigen and CD8 were not related to the differentiation degree of the tumor or lymph node metastasis (P>0.05). A positive correlation was found between HLA class I antigen expression and CD8 expression.


CONCLUSIONS
The expressions of HLA class I antigen and CD8 are down-regulated or deleted in CIN and cervical cancer, and they may play important roles in the development and progression of CIN and cervical cancer.
Qi
Yue
Y
Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, Shenyang 110004, China. qiyue1980@yahoo.com.cn
Huang
Jin-Shuang
JS
Wang
Dong-dong
DD
Zhang
Fan
F
Zhang
Shu-lan
SL
D000328:Adult; D000368:Aged; D016827:CD8 Antigens / Q000276:immunology* / Q000378:metabolism; D015536:Down-Regulation; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000473:pathology
D016827:CD8 Antigens; D015395:Histocompatibility Antigens Class I